spacer
The Healthcare Sales & Marketing Network celebrates 26 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  myelofibrosis 

 HSMN NewsFeed - 10 May 2023
Sobi to Acquire CTI BioPharma
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 21 Jul 2022
Karyopharm and Menarini Group Receive Full Marketing Authorisation from the European Commission for NEXPOVIO(R) (selinexor) for the Treatment of Patients with Multiple Myeloma After at Least One Prior Therapy
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 14 Apr 2022
NCCN Guidelines(R) Recommend VONJO(TM) (pacritinib) for the Treatment of Myeloproliferative Neoplasms
Biopharmaceuticals Oncology
 HSMN NewsFeed - 2 Sep 2021
Disc Medicine Announces $90 Million Series B Financing to Advance Portfolio of Clinical-Stage Therapies for Hematologic Diseases
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 12 Jul 2021
Cardiff Oncology Announces the Appointments of Katherine L. Ruffner, M.D., as Chief Medical Officer and James E. Levine as Chief Financial Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 31 Mar 2021
CTI BioPharma Announces Completion of Rolling Submission of New Drug Application (NDA) for Pacritinib in Myelofibrosis Patients with Severe Thrombocytopenia
Biopharmaceuticals FDA
 HSMN NewsFeed - 1 Jul 2020
Sumitomo Dainippon Pharma Oncology Announces Its Formation Through Merger of Tolero and Boston Biomedical
Biopharmaceuticals Oncology Mergers & Acquisitions
 HSMN NewsFeed - 26 May 2020
Sierra Oncology Appoints Dr. Stephen Dilly as President and Chief Executive Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 2 Mar 2020
Primmune Therapeutics Raises $7 Million Seed Financing to Develop Novel Oral TLR7 Immunotherapies for Cancer and Acute Viral Diseases
Biopharmaceuticals Venture Capital Personnel
 HSMN NewsFeed - 6 Dec 2019
Apexigen Expands Leadership Team with Two Key Appointments in CMC and Clinical Development
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 22 Jul 2019
Geron Enhances Oncology Expertise to Advance Corporate Objectives
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 1 Feb 2019
CTI BioPharma Receives Results of the CHMP Oral Explanation for Pacritinib in the Treatment of Myelofibrosis and Provides Development Update
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 17 Dec 2018
PharmaEssentia and AOP Orphan Receive Positive CHMP Opinion For Besremi(TM) (Ropeginterferon alfa-2b) For Treatment Of Polycythemia Vera (PV) In EU
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 13 Dec 2018
CTI BioPharma Announces Restructuring Plan
Biopharmaceuticals Personnel
 HSMN NewsFeed - 22 Aug 2018
Sierra Oncology Obtains Debt Facility from Silicon Valley Bank to Acquire and Advance Momelotinib
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 22 Aug 2018
Sierra Oncology Acquires Momelotinib, an Investigational Janus Kinase (JAK) 1/2 and Activin Receptor Type 1 (ACVR1) Inhibitor for Myelofibrosis, from Gilead Sciences
Biopharmaceuticals Oncology Acquisitions
 HSMN NewsFeed - 9 Jul 2018
Results of Phase III (PIX306) Trial Evaluating Progression-Free Survival of PIXUVRI(R) (pixantrone) Combined with Rituximab in Patients with Aggressive B-cell Non-Hodgkin Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 9 Mar 2018
CTI BioPharma Announces Publication of Pacritinib Phase 3 PERSIST-2 Clinical Trial in JAMA Oncology
Biopharmaceuticals Oncology
 HSMN NewsFeed - 26 Sep 2017
CTI BioPharma Appoints Laurent Fischer as New Chairman of the Board and Announces Management Promotions
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 24 Jul 2017
CTI BioPharma Appoints Biotechnology Industry Veteran Laurent Fischer, M.D., to Board of Directors
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 27 Feb 2017
CTI BioPharma Announces Appointment of Hematology/Oncology Clinical Expert Adam Craig, M.D., Ph.D., as President and CEO
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 30 Mar 2016
Curis Announces Expansion of Executive Team
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 11 Feb 2016
Incyte Announces Decision to Discontinue JANUS Studies of Ruxolitinib plus Capecitabine in Patients with Advanced or Metastatic Pancreatic Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 8 Feb 2016
CTI BioPharma Provides Update On Investigational Agent Pacritinib
Biopharmaceuticals Oncology
 HSMN NewsFeed - 17 Mar 2015
Jakavi(R) (ruxolitinib) Receives European Commission Approval as First Targeted Therapy for Patients with Polycythemia Vera
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 3 Feb 2015
CTI BioPharma Announces Independent DMC Recommendation to Continue GOG-0212 Phase 3 Study of OPAXIO(TM) as Maintenance Therapy in Ovarian Cancer, an NRG Oncology/GOG Study
Biopharmaceuticals Oncology
 HSMN NewsFeed - 12 Jan 2015
CTI BioPharma Appoints Alan K. Burnett, M.D. As Therapeutic Area Lead, Myeloid Diseases
Biopharmaceuticals Personnel
 HSMN NewsFeed - 17 Sep 2014
CTI BioPharma And Servier Announce Exclusive License And Collaboration Agreement To Develop And Commercialize PIXUVRI(R)
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 30 May 2014
Cell Therapeutics, Inc. Announces Change of Name to CTI BioPharma Corp.
Biopharmaceuticals Oncology
 HSMN NewsFeed - 7 Mar 2014
Incyte Announces Positive Top-Line Results from Phase III Study of Ruxolitinib in Patients with Polycythemia Vera
Biopharmaceuticals
 HSMN NewsFeed - 22 Oct 2012
Jim Daly to Join Incyte as Executive Vice President and Chief Commercial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 15 Oct 2012
Promedior Appoints Elizabeth Trehu, M.D., as Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 15 Oct 2012
Promedior Expands Series D Round of Financing to Total $24.5 Million to Advance Pipeline of Pentraxin-2 Therapeutics for Fibrotic Diseases
Biopharmaceuticals Venture Capital Personnel
 HSMN NewsFeed - 14 Jun 2012
Cell Therapeutics Appoints New Chief Medical Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 15 May 2012
Promedior Appoints Suzanne L. Bruhn, Ph.D., as President and Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 15 Mar 2011
Incyte’s Ruxolitinib (INCB18424) Meets Primary Endpoint in Second Phase III Study
Biopharmaceuticals Oncology
 HSMN NewsFeed - 14 Oct 2010
YM Biosciences Appoints Dr. Nick Glover as Chief Executive Officer and Announces Annual Meeting
Biopharmaceuticals Personnel
 HSMN NewsFeed - 10 Dec 2007
Pivotal Phase 3 NPLATE(TM) Study in Non-Splenectomized Patients Met Primary Endpoints
Biopharmaceuticals
 HSMN NewsFeed - 12 Jul 2007
TargeGen, Inc. Closes $40M Series 'D' Financing Round
Biopharmaceuticals Venture Capital
Return to NewsFeed  

 Additional items found! 6

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 6 additional stories matching:
myelofibrosis
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.